Sichuan Huiyu Pharmaceutical Co., Ltd.
688553.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.42B
Close$
$-9.22
179.5% downside
Current Fair Value
179.5% downsideOvervalued by 179.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.42 Billion |
|---|---|
| Enterprise Value | $5.80 Billion |
| Dividend Yield | $0.20 (1.69%) |
| Earnings per Share | $-0.06 |
| Beta | 0.52 |
| Outstanding Shares | 625,900,859 |
Return
| Return on Equity | 3.06% |
|---|---|
| Return on Assets | 2.19% |
| Return on Invested Capital | 2.17% |
Valuation & Multiples
| P/E Ratio | 46.02 |
|---|---|
| PEG | -27.9 |
| Price to Sales | 11.59 |
| Price to Book Ratio | 2.32 |
| Enterprise Value to Revenue | 5.29 |
| Enterprise Value to EBIT | 70.09 |
| Enterprise Value to Net Income | 50 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sichuan Huiyu Pharmaceutical Co., Ltd.
1,366 employees
CEO: Zhao Ding Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, ox...